CO6620019A2 - Métodos de tratamiento de cander de vejiga - Google Patents
Métodos de tratamiento de cander de vejigaInfo
- Publication number
- CO6620019A2 CO6620019A2 CO12236221A CO12236221A CO6620019A2 CO 6620019 A2 CO6620019 A2 CO 6620019A2 CO 12236221 A CO12236221 A CO 12236221A CO 12236221 A CO12236221 A CO 12236221A CO 6620019 A2 CO6620019 A2 CO 6620019A2
- Authority
- CO
- Colombia
- Prior art keywords
- cander
- bladder
- treatment methods
- bladder cancer
- albumine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención provee métodos y composiciones para tratamiento de cáncer de vejiga, incluyendo cáncer de vejiga metastático y cáncer de vejiga no musculo invasivo al administrar una composición que comprende nanopartículas que comprenden un taxano y una albumina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39680010P | 2010-06-02 | 2010-06-02 | |
US201161449513P | 2011-03-04 | 2011-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6620019A2 true CO6620019A2 (es) | 2013-02-15 |
Family
ID=45067028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12236221A CO6620019A2 (es) | 2010-06-02 | 2012-12-28 | Métodos de tratamiento de cander de vejiga |
Country Status (20)
Country | Link |
---|---|
US (2) | US20130266659A1 (es) |
EP (1) | EP2575803B1 (es) |
JP (1) | JP2013527232A (es) |
KR (1) | KR20130109025A (es) |
CN (1) | CN103221042B (es) |
AU (1) | AU2011261684B2 (es) |
BR (1) | BR112012030699A2 (es) |
CA (1) | CA2801314A1 (es) |
CO (1) | CO6620019A2 (es) |
CR (1) | CR20120619A (es) |
ES (1) | ES2639038T3 (es) |
MX (1) | MX343671B (es) |
MY (1) | MY188911A (es) |
NI (1) | NI201200175A (es) |
NZ (2) | NZ604029A (es) |
PH (1) | PH12016502066A1 (es) |
RU (1) | RU2621640C2 (es) |
SG (1) | SG186109A1 (es) |
WO (1) | WO2011153009A1 (es) |
ZA (1) | ZA201208815B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
CN104587479A (zh) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
PT1853250E (pt) | 2005-02-18 | 2012-02-03 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
CN103054798B (zh) * | 2005-08-31 | 2021-03-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
AU2007334360B2 (en) | 2006-12-14 | 2013-10-17 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
HUE039643T2 (hu) * | 2007-03-07 | 2019-01-28 | Abraxis Bioscience Llc | Rapamicin rákellenes szert és albumint tartalmazó nanorészecske |
EP2155188B1 (en) | 2007-06-01 | 2013-10-09 | Abraxis BioScience, LLC | Methods and compositions for treating recurrent cancer |
WO2010121000A1 (en) | 2009-04-15 | 2010-10-21 | Abraxis Bioscience, Llc | Prion-free nanoparticle compositions and methods |
PL2552438T3 (pl) | 2010-03-26 | 2016-12-30 | Sposoby leczenia raka wątrobowokomórkowego | |
CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
KR20190130050A (ko) | 2010-06-04 | 2019-11-20 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
RU2016103126A (ru) * | 2010-06-07 | 2018-11-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы комбинированной терапии для лечения пролиферативных заболеваний |
KR20200051841A (ko) | 2011-04-28 | 2020-05-13 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
CN109771377A (zh) | 2011-12-14 | 2019-05-21 | 阿布拉科斯生物科学有限公司 | 用于颗粒冻干或冷冻的聚合物赋形剂 |
DK177379B1 (en) * | 2012-03-29 | 2013-02-25 | Entomopharm Aps | Insect-based model to study the effect and integrity of nanoparticles on blood-brain barrier function |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
KR102191311B1 (ko) | 2013-03-12 | 2020-12-15 | 아브락시스 바이오사이언스, 엘엘씨 | 폐암의 치료 방법 |
MX2015011783A (es) * | 2013-03-13 | 2015-12-01 | Abraxis Bioscience Llc | Metodos para tratar tumores solidos pediatricos. |
CA2903548A1 (en) * | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
AU2014368898B2 (en) | 2013-12-20 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Combination therapy with neoantigen vaccine |
CN104434808A (zh) * | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗性纳米粒子及其制备方法 |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
EP3297660A2 (en) | 2015-05-20 | 2018-03-28 | The Broad Institute Inc. | Shared neoantigens |
CA3026452C (en) | 2015-06-04 | 2023-03-21 | Crititech, Inc. | Nozzle assembly and methods for use |
MX2017016519A (es) * | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Biomarcadores para composiciones de nanoparticulas. |
KR102606071B1 (ko) | 2015-06-29 | 2023-11-27 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
US20170027941A1 (en) * | 2015-07-31 | 2017-02-02 | Pharmacyclics Llc | Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof |
KR102490665B1 (ko) | 2016-04-04 | 2023-01-27 | 크리티테크, 인크. | 고형 종양의 치료 방법 |
MX2018013432A (es) * | 2016-05-06 | 2019-08-12 | Taris Biomedical Llc | Metodo para tratar cancer urotelial del tracto inferior. |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
ES2980123T3 (es) | 2017-06-09 | 2024-09-30 | Crititech Inc | Composiciones para uso en el tratamiento de quistes epiteliales mediante inyección intraquística de partículas antineoplásicas |
KR20210118468A (ko) | 2017-06-14 | 2021-09-30 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
WO2019023388A1 (en) | 2017-07-25 | 2019-01-31 | Taris Biomedical Llc | METHODS OF TREATING TUMOR METASTASIS |
CA3076919A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
EP3706763A4 (en) | 2017-11-08 | 2021-08-11 | TARIS Biomedical LLC | METHODS OF TREATMENT AND MAINTENANCE THERAPY FOR BLADDER CANCER USING GEMCITABINE |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
US20190209515A1 (en) * | 2018-01-05 | 2019-07-11 | Crititech, Inc. | Treatment of Bladder Cancer by Intratumoral Injection of Taxane Particles |
RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
WO2020072090A1 (en) * | 2018-10-03 | 2020-04-09 | Crititech, Inc. | Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls) |
AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
WO2024102620A2 (en) * | 2022-11-09 | 2024-05-16 | Tempest Therapeutics, Inc. | Triazolone compounds and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
DE69435342D1 (de) * | 1993-07-19 | 2011-05-05 | Angiotech Pharm Inc | Anti-Angiogene Mittel und Verfahren zu deren Verwendung |
GB9811598D0 (en) * | 1998-05-30 | 1998-07-29 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
RU2361615C2 (ru) * | 2002-12-09 | 2009-07-20 | Абраксис Байосайенс, Ллс. | Композиции и способы доставки фармакологических агентов |
CN104587479A (zh) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
PT1853250E (pt) * | 2005-02-18 | 2012-02-03 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
NZ592132A (en) | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
JP5641927B2 (ja) * | 2007-04-13 | 2014-12-17 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Sparc及びその使用方法 |
CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
EP2367425B1 (en) * | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
SG178873A1 (en) * | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
-
2011
- 2011-05-20 NZ NZ604029A patent/NZ604029A/en unknown
- 2011-05-20 ES ES11790192.6T patent/ES2639038T3/es active Active
- 2011-05-20 SG SG2012088019A patent/SG186109A1/en unknown
- 2011-05-20 CN CN201180038029.3A patent/CN103221042B/zh active Active
- 2011-05-20 CA CA2801314A patent/CA2801314A1/en not_active Abandoned
- 2011-05-20 JP JP2013513207A patent/JP2013527232A/ja active Pending
- 2011-05-20 AU AU2011261684A patent/AU2011261684B2/en active Active
- 2011-05-20 BR BR112012030699A patent/BR112012030699A2/pt not_active Application Discontinuation
- 2011-05-20 US US13/701,003 patent/US20130266659A1/en not_active Abandoned
- 2011-05-20 EP EP11790192.6A patent/EP2575803B1/en not_active Revoked
- 2011-05-20 NZ NZ708506A patent/NZ708506A/en unknown
- 2011-05-20 RU RU2012157805A patent/RU2621640C2/ru active
- 2011-05-20 KR KR1020127034199A patent/KR20130109025A/ko not_active Application Discontinuation
- 2011-05-20 WO PCT/US2011/037449 patent/WO2011153009A1/en active Application Filing
- 2011-05-20 MX MX2012013909A patent/MX343671B/es active IP Right Grant
- 2011-05-20 MY MYPI2012005167A patent/MY188911A/en unknown
-
2012
- 2012-11-22 ZA ZA2012/08815A patent/ZA201208815B/en unknown
- 2012-11-30 NI NI201200175A patent/NI201200175A/es unknown
- 2012-12-10 CR CR20120619A patent/CR20120619A/es unknown
- 2012-12-28 CO CO12236221A patent/CO6620019A2/es unknown
-
2013
- 2013-03-01 US US13/782,984 patent/US20140056986A1/en not_active Abandoned
-
2016
- 2016-10-18 PH PH12016502066A patent/PH12016502066A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2012013909A (es) | 2013-02-21 |
PH12016502066A1 (en) | 2019-02-04 |
NZ708506A (en) | 2016-08-26 |
RU2012157805A (ru) | 2014-07-20 |
CR20120619A (es) | 2014-03-21 |
MY188911A (en) | 2022-01-13 |
SG186109A1 (en) | 2013-01-30 |
EP2575803A1 (en) | 2013-04-10 |
NZ604029A (en) | 2015-07-31 |
AU2011261684A1 (en) | 2013-01-10 |
CN103221042B (zh) | 2016-02-10 |
ZA201208815B (en) | 2014-01-29 |
CA2801314A1 (en) | 2011-12-08 |
US20140056986A1 (en) | 2014-02-27 |
NI201200175A (es) | 2013-05-13 |
US20130266659A1 (en) | 2013-10-10 |
EP2575803B1 (en) | 2017-07-26 |
WO2011153009A1 (en) | 2011-12-08 |
BR112012030699A2 (pt) | 2016-09-13 |
AU2011261684B2 (en) | 2016-09-15 |
KR20130109025A (ko) | 2013-10-07 |
ES2639038T3 (es) | 2017-10-25 |
EP2575803A4 (en) | 2014-01-01 |
CN103221042A (zh) | 2013-07-24 |
RU2621640C2 (ru) | 2017-06-06 |
MX343671B (es) | 2016-11-16 |
JP2013527232A (ja) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6620019A2 (es) | Métodos de tratamiento de cander de vejiga | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
EA201400178A1 (ru) | Лечение рака молочной железы | |
IN2012DN02018A (es) | ||
MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
GB201020860D0 (en) | Disulfiram formulation and uses thereof | |
TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
BR112014008294A2 (pt) | anticorpo anti c-met e usos do mesmo | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
BR112014030416A2 (pt) | composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção. | |
CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
BR112013006567A2 (pt) | métodos e composições para tratamento de câncer de pulmão | |
MX358254B (es) | Métodos para el tratamiento de cáncer de mama. | |
TW201611831A (en) | Novel antitumoral use of CABAZITAXEL | |
ECSP14013195A (es) | Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata. | |
GT201500071A (es) | Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3 | |
ECSP14011792A (es) | Inhibidores de iap | |
CL2013003324A1 (es) | Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón. | |
WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
ZA201300426B (en) | Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |